Related Experiment Video

Updated: Aug 21, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here?

Raghvendra K Dubey1, Bruno Imthurn, Lefteris C Zacharia

  • 1Center for Clinical Pharmacology, University of Pittsburgh Medical Center, Pittsburgh, Pa, USA. Raghvendra.dubey@usz.ch

Hypertension (Dallas, Tex. : 1979)
|October 13, 2004
PubMed

Insights

Hormone replacement therapy was believed to protect cardiovascular health. However, major studies revealed it may increase cardiovascular disease risk, prompting a re-evaluation of its use.

Area of Science:

  • Cardiovascular Science
  • Endocrinology
  • Clinical Trials

Background:

  • Previous observational and experimental studies suggested hormone replacement therapy (HRT) conferred cardiovascular protection.
  • This widely accepted notion was challenged by large-scale clinical trials.

Purpose of the Study:

  • To critically analyze the discrepancies between earlier findings and recent large-scale study results regarding HRT and cardiovascular disease (CVD).
  • To explore potential reasons for the unexpected outcomes and propose future research directions in HRT and CVD.

Main Methods:

  • Review of observational human studies, animal experiments, and cell studies.
  • Analysis of pivotal clinical trials, including the Women's Health Initiative Study and the Heart and Estrogen/Progestin Replacement Study.
  • Critical appraisal of the evidence base for HRT's cardiovascular effects.

Main Results:

  • The Women's Health Initiative Study and the Heart and Estrogen/Progestin Replacement Study contradicted prior beliefs.
  • These studies indicated that HRT, particularly estrogen/progestin therapy, may elevate the risk of cardiovascular disease.
  • A significant shift in understanding the cardiovascular implications of HRT was established.

Conclusions:

  • The established understanding of HRT's cardiovascular benefits was fundamentally challenged.
  • There is a critical need to investigate the underlying mechanisms and specific patient populations affected by HRT's cardiovascular risks.
  • Future research should focus on reconciling conflicting data and guiding safer therapeutic strategies.

More Related Videos

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

Implantation of Total Artificial Heart in Congenital Heart Disease07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...